Effective April 28, 2026, the United States formally acknowledged medical marijuana as a legitimate controlled substance by moving it to Schedule III of the Controlled Substances Act - a shift that does far more than change a number on a federal registry. For the first time, state-licensed medical marijuana operators can apply for DEA registration, access the federal regulatory framework, and, critically, participate in international import and export markets. The order, issued under 21 U.S.C. 811(d)(1) by the acting Attorney General, is a final rule, not a proposal - and it landed with considerably more force than most observers anticipated.
What Actually Changed - and What Didn't
The rescheduling is targeted, not sweeping. The order covers three specific categories: marijuana as listed in 21 CFR 1308.11(d)(23), marijuana extracts as defined in 21 CFR 1308.11(d)(58), and naturally occurring Delta-9-THC derived from the marijuana plant, excluding mature stalks and seeds. What it does not cover is adult-use marijuana - the recreational market that operates legally under state law in roughly half the country. That product remains in Schedule I. A separate rescheduling hearing for adult-use marijuana is scheduled for June 29, 2026.
The distinction matters enormously. A dispensary holding a state medical license is now operating in a federally recognized framework, with a path to DEA registration. A dispensary selling recreational product to the same customer base, under the same roof, is still technically a federal narcotics operation. The dual reality of American cannabis law didn't disappear on April 28 - it just got more complicated.
The Treaty Mechanism Nobody Was Talking About
Here's the thing about how this order was issued: it bypassed the standard rulemaking process entirely. The acting Attorney General invoked Section 811(d)(1), a provision that allows the executive to reschedule a substance when doing so brings the United States into better alignment with its international treaty obligations - specifically, the 1961 Single Convention on Narcotic Drugs. Under this mechanism, the Department of Justice is not required to obtain a scheduling recommendation from the Department of Health and Human Services, though HHS did provide one in 2023. The Attorney General chose to reference that recommendation anyway, framing it as discretionary alignment rather than procedural necessity.
The Single Convention is the same treaty framework that has long constrained U.S. flexibility on cannabis scheduling. Using it as the legal vehicle for rescheduling - rather than fighting it - is a policy inversion worth noting. The United States is now citing its international obligations as the reason to liberalize, not restrict.
DEA Registration and the Path to Global Markets
For state-licensed medical marijuana operators, the practical implications run deep. The order establishes an expedited DEA registration process: existing state credentials can be submitted as conclusive evidence of authorization, and applications filed within 60 days of publication must be processed within six months. Early applicants may continue operating under their state licenses while federal review is pending.
Once registered with the DEA, those operators gain something entirely new - eligibility to apply for import and export permits. The order amends 21 CFR 1312.30 to add FDA-approved marijuana products and state-licensed medical marijuana to the list of nonnarcotic Schedule III through V substances subject to the import/export permit requirement. That amendment, quiet as it sounds in regulatory prose, opens a door to international commerce that has been firmly shut since federal prohibition began.
The order also addressed DEA's existing regulatory definition of "medicinal cannabis," which had previously required such products to be FDA-approved and marketable under the Food, Drug, and Cosmetic Act - a standard that, by design, excluded virtually every state-legal medical product. That definition has now been amended to bring state-licensed medical marijuana inside the tent.
State registrants also receive meaningful operational flexibility. They may rely on state-law requirements for labeling, packaging, disposal, and physical security, rather than defaulting to federal specifications - with one exception: the statutory warning label required by 21 U.S.C. 825(c) must appear on all products.
What Comes Next, and Why Judicial Review Will Define It
The order's ambition is real. So are its vulnerabilities. Amending DEA regulations through a final order rather than notice-and-comment rulemaking will face scrutiny. Whether the 811(d)(1) mechanism provides sufficient statutory authority to accomplish everything this order attempts - particularly the integration of state licensing systems into the federal registration framework - is a question federal courts will almost certainly be asked to answer.
Adult-use operators, meanwhile, are watching from Schedule I. The June 2026 hearing could extend rescheduling to recreational marijuana, but it could also take years, spawn litigation, or produce a narrower outcome. The bifurcated system now in place - medical marijuana federally acknowledged, recreational marijuana federally prohibited - is not a permanent resolution. It's a staging post.
For the international dimension, the practical question is whether trading partners will move quickly enough to matter. Countries operating under the Single Convention have their own domestic frameworks, and import/export markets for cannabis are nascent even where they exist legally. The United States joining that space is significant. Building actual supply chains, regulatory agreements, and commercial relationships will take years - and require both the DEA and foreign regulators to make decisions they have never made before.
What April 28, 2026 did, in plain terms, was close an era of categorical federal denial and open one of conditional federal recognition. The fine print is dense, the litigation risk is real, and the international market is barely formed. But the direction changed. That is not nothing.
